PASG
Passage Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.72
−0.74%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +34.7%
- EBIT
- +35.8%
- EPS
- +38.0%
- Free cash flow
- +7.2%
- Operating cash flow
- +7.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +56.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- +27.9%
- EBIT
- +38.7%
- Net income
- +29.7%
- EPS
- +33.1%
- Free cash flow
- +34.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026